The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis

Atherosclerosis

Volumn 249, Issue , 2016, Pages 200-208

  Hennuyer, Nathalie ^a,b,c,d   Duplan, Isabelle ^a,b,c,d   Paquet, Charlotte ^a,b,c,d   Vanhoutte, Jonathan ^a,b,c,d   Woitrain, Eloise ^a,b,c,d   Touche, Véronique ^a,b,c,d   Colin, Sophie ^a,b,c,d   Vallez, Emmanuelle ^a,b,c,d   Lestavel, Sophie ^a,b,c,d   Lefebvre, Philippe ^a,b,c,d   Staels, Bart ^a,b,c,d  

^a EGID FR3508 European Genomics Institute of Diabetes   (France)

^b UNIV LILLE   (France)

^c INSERM UMR 1011 ^*  (France)

^d INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Atherosclerosis; Inflammation; Lipids; Pemafibrate; Reverse cholesterol transport; SPPARM

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E2; CARBOXYMETHYLCELLULOSE; CHYLOMICRON; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEMAFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN; (R)-2-(3-((BENZOXAZOL-2-YL-D4 (3-(4-METHOXYPHENOXY-D7)PROPYL)AMINO)METHYL)PHENOXY) BUTANOIC ACID; BENZOXAZOLE DERIVATIVE; BUTYRIC ACID DERIVATIVE; CHOLESTEROL; LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; CACO 2 CELL LINE; CELL DIFFERENTIATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DYSLIPIDEMIA; FECES; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INTESTINE EPITHELIUM; INTESTINE EPITHELIUM CELL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN DIET; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CACO-2 CELL LINE; CARDIOVASCULAR DISEASE; CHEMISTRY; EPITHELIUM; HOMOZYGOTE; INTESTINE; LIPID METABOLISM; METABOLISM; RISK FACTOR; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BENZOXAZOLES; BIOLOGICAL TRANSPORT; BUTYRATES; CACO-2 CELLS; CARDIOVASCULAR DISEASES; CHOLESTEROL; DYSLIPIDEMIAS; EPITHELIUM; FEMALE; HOMOZYGOTE; HUMANS; INFLAMMATION; INTESTINES; LIGANDS; LIPID METABOLISM; LIPOPROTEINS, HDL; MACROPHAGES; MICE; PPAR ALPHA; RISK FACTORS;

EID: 84963956656     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.03.003     Document Type: Article

References (43)

1. [1] Libby, P., Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32 (2012), 2045–2051.
2. [2] Moore, K.J., Sheedy, F.J., Fisher, E.A., Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol. 13 (2013), 709–721.
3. [3] Zandbergen, F., Plutzky, J., PPARalpha in atherosclerosis and inflammation. Biochim. Biophys. Acta 1771 (2007), 972–982.
4. [4] Staels, B., Maes, M., Zambon, A., Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat. Clin. Pract. Cardiovasc Med. 5 (2008), 542–553.
5. [5] Tenenbaum, A., Fisman, E.Z., Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol., 11, 2012, 125.
6. [6] Pawlak, M., Lefebvre, P., Staels, B., General molecular biology and architecture of nuclear receptors. Curr. Top. Med. Chem. 12 (2012), 486–504.
7. [7] Pawlak, M., Lefebvre, P., Staels, B., Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 62 (2015), 720–733.
8. [8] Peters, J.M., Hennuyer, N., Staels, B., Fruchart, J.C., Fievet, C., Gonzalez, F.J., Auwerx, J., Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J. Biol. Chem. 272 (1997), 27307–27312.
9. [9] Schoonjans, K., Peinado-Onsurbe, J., Lefebvre, A.M., Heyman, R.A., Briggs, M., Deeb, S., Staels, B., Auwerx, J., PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a ppre in the lipoprotein lipase gene. EMBO J. 15 (1996), 5336–5348.
10. [10] Vu-Dac, N., Gervois, P., Jakel, H., Nowak, M., Bauge, E., Dehondt, H., Staels, B., Pennacchio, L.A., Rubin, E.M., Fruchart-Najib, J., Fruchart, J., Apolipoprotein a5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J. Biol. Chem. 278 (2003), 17982–17985.
11. [11] Staels, B., Vu-Dac, N., Kosykh, V.A., Saladin, R., Fruchart, J.C., Dallongeville, J., Auwerx, J., Fibrates downregulate apolipoprotein c-iii expression independent of induction of peroxisomal acyl coenzyme a oxidase. a potential mechanism for the hypolipidemic action of fibrates. J. Clin. Invest. 95 (1995), 705–712.
12. [12] Hertz, R., Bishara-Shieban, J., Bar-Tana, J., Mode of action of peroxisome proliferators as hypolipidemic drugs. suppression of apolipoprotein c-iii. J. Biol. Chem. 270 (1995), 13470–13475.
13. [13] Haubenwallner, S., Essenburg, A.D., Barnett, B.C., Pape, M.E., DeMattos, R.B., Krause, B.R., Minton, L.L., Auerbach, B.J., Newton, R.S., Leff, T., et al. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein c-iii expression: a potential physiologic basis for their mode of action. J. Lipid Res. 36 (1995), 2541–2551.
14. [14] Colin, S., Briand, O., Touche, V., Wouters, K., Baron, M., Pattou, F., Hanf, R., Tailleux, A., Chinetti, G., Staels, B., Lestavel, S., Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production. Eur. Heart J. 34 (2013), 2566–2574.
15. [15] Vu-Dac, N., Schoonjans, K., Laine, B., Fruchart, J.C., Auwerx, J., Staels, B., Negative regulation of the human apolipoprotein a-i promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J. Biol. Chem. 269 (1994), 31012–31018.
16. [16] Berthou, L., Duverger, N., Emmanuel, F., Langouët, S., Auwerx, J., Guillouzo, A., Fruchart, J.C., Rubin, E., Denèfle, P., Staels, B., Branellec, D., Opposite regulation of human versus mouse apolipoprotein a-i by fibrates in human apolipoprotein a-i transgenic mice. J. Clin. Invest 97 (1996), 2408–2416.
17. [17] Chinetti, G., Lestavel, S., Fruchart, J., Clavey, V., Staels, B., Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ. Res. 92 (2003), 212–217.
18. [18] Chinetti, G., Lestavel, S., Bocher, V., Remaley, A.T., Neve, B., Torra, I.P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., Brewer, H.B., Fruchart, J.C., Clavey, V., Staels, B., PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the abca1 pathway. Nat. Med. 7 (2001), 53–58.
19. [19] Chinetti, G., Gbaguidi, F.G., Griglio, S., Mallat, Z., Antonucci, M., Poulain, P., Chapman, J., Fruchart, J.C., Tedgui, A., Najib-Fruchart, J., Staels, B., Cla-1/sr-bi is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 101 (2000), 2411–2417.
20. [20] Zhang, Y., Zanotti, I., Reilly, M.P., Glick, J.M., Rothblat, G.H., Rader, D.J., Overexpression of apolipoprotein a-i promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 108 (2003), 661–663.
21. [21] Moore, R.E., Navab, M., Millar, J.S., Zimetti, F., Hama, S., Rothblat, G.H., Rader, D.J., Increased atherosclerosis in mice lacking apolipoprotein a-i attributable to both impaired reverse cholesterol transport and increased inflammation. Circ. Res. 97 (2005), 763–771.
22. [22] Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J.M., Gonzalez, F.J., Fruchart, J.C., Tedgui, A., Haegeman, G., Staels, B., Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors nf-kappab and ap-1. J. Biol. Chem. 274 (1999), 32048–32054.
23. [23] Pawlak, M., Baugé, E., Bourguet, W., De Bosscher, K., Lalloyer, F., Tailleux, A., Lebherz, C., Lefebvre, P., Staels, B., The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice. Hepatology 60 (2014), 1593–1606.
24. [24] Staels, B., Koenig, W., Habib, A., Merval, R., Lebret, M., Torra, I.P., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J.C., Najib, J., Maclouf, J., Tedgui, A., Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393 (1998), 790–793.
25. [25] Marx, N., Sukhova, G.K., Collins, T., Libby, P., Plutzky, J., PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99 (1999), 3125–3131.
26. [26] Lalloyer, F., Wouters, K., Baron, M., Caron, S., Vallez, E., Vanhoutte, J., Baugé, E., Shiri-Sverdlov, R., Hofker, M., Staels, B., Tailleux, A., Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein e2 knock-in mice. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 1573–1579.
27. [27] Duez, H., Chao, Y., Hernandez, M., Torpier, G., Poulain, P., Mundt, S., Mallat, Z., Teissier, E., Burton, C.A., Tedgui, A., Fruchart, J., Fiévet, C., Wright, S.D., Staels, B., Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J. Biol. Chem. 277 (2002), 48051–48057.
28. [28] Srivastava, R.A.K., Jahagirdar, R., Azhar, S., Sharma, S., Bisgaier, C.L., Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in ldl receptor-deficient mice. Mol. Cell. Biochem. 285 (2006), 35–50.
29. [29] Babaev, V.R., Ishiguro, H., Ding, L., Yancey, P.G., Dove, D.E., Kovacs, W.J., Semenkovich, C.F., Fazio, S., Linton, M.F., Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 116 (2007), 1404–1412.
30. [30] Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S.J., Grobbee, D.E., Cass, A., Chalmers, J., Perkovic, V., Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375 (2010), 1875–1884.
31. [31] Staels, B., Fibrates in cvd: a step towards personalised medicine. Lancet 375 (2010), 1847–1848.
32. [32] Liu, Z., Hu, M., Chan, P., Tomlinson, B., Early investigational drugs targeting PPAR-α for the treatment of metabolic disease. Expert Opin. Investig. Drugs, 2015, 1–11.
33. [33] Gervois, P., Fruchart, J., Staels, B., Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat. Clin. Pract. Endocrinol. Metab. 3 (2007), 145–156.
34. [34] Fruchart, J., Selective peroxisome proliferator-activated receptor α modulators (spparmα): the next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc. Diabetol., 12, 2013, 82.
35. [35] Takizawa, T., Inokuchi, Y., Goto, S., Nihira, K., Yoshinaka, Y., Abe, K., Inoue, K., Tanabe, S., The mechanisms of k-877, a highly potent and selectiveppara modulator, on regulation of synthesis, secretion and metabolisms of triglycerides and cholesterol. Circulation, 128, 2013, A12867.
36. [36] Ishibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., Kodoma, T., Efficacy and safety of k-877, a potent and selective PPARa agonist, in Japanese patients with dyslipidemia. Circulation, 128, 2013, A10718.
37. [37] Camont, L., Lhomme, M., Rached, F., Le Goff, W., Nègre-Salvayre, A., Salvayre, R., Calzada, C., Lagarde, M., Chapman, M.J., Kontush, A., Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler. Thromb. Vasc. Biol. 33 (2013), 2715–2723.
38. [38] Sviridov, D., Mukhamedova, N., Remaley, A.T., Chin-Dusting, J., Nestel, P., Antiatherogenic functionality of high density lipoprotein: how much versus how good. J. Atheroscler. Thromb. 15 (2008), 52–62.
39. [39] Yamashita, S., Ishibshi, S., Arai, H., Araki, E., Yokote, K., Kodoma, T., Comparison of the effect of novel peroxisome proliferator-activated receptor alpha agonist k-877 and fenofibrate on high density lipoprotein subclass distribution determined by high-performance liquid chromatography in patients with dyslipidemia. Circulation, 128, 2013, A15652.
40. [40] Camont, L., Chapman, M.J., Kontush, A., Biological activities of hdl subpopulations and their relevance to cardiovascular disease. Trends Mol. Med. 17 (2011), 594–603.
41. [41] Rohatgi, A., Khera, A., Berry, J.D., Givens, E.G., Ayers, C.R., Wedin, K.E., Neeland, I.J., Yuhanna, I.S., Rader, D.R., de Lemos, J.A., Shaul, P.W., Hdl cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 371 (2014), 2383–2393.
42. [42] Rotllan, N., Llaverías, G., Julve, J., Jauhiainen, M., Calpe-Berdiel, L., Hernández, C., Simó, R., Blanco-Vaca, F., Escolà-Gil, J.C., Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo. Biochim. Biophys. Acta 1811 (2011), 104–110.
43. [43] Ziouzenkova, O., Perrey, S., Asatryan, L., Hwang, J., MacNaul, K.L., Moller, D.E., Rader, D.J., Sevanian, A., Zechner, R., Hoefler, G., Plutzky, J., Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 2730–2735.